Clinical Development & Data
Trial architecture, endpoints, recruitment, comparator signals, investigator interpretation, and the way evidence in dermatology will be read downstream.
Dermatology
ICG works across dermatology environments where clinical differentiation, visible outcomes, treatment sequencing, topical and biologic delivery, access, and specialist organization interact.
The work includes dermatology competitive intelligence, psoriasis, atopic dermatitis, prurigo nodularis, topical therapies, biologic and biosimilar entry, pricing, launch, field-force design, and longitudinal monitoring.
Visible Outcomes, Complex Competitive Systems.
Dermatology markets combine subjective and objective outcomes, rapid class evolution, specialist and primary-care boundaries, topical and systemic treatment, adherence, contracting, and patient expectations.
ICG reconstructs how those conditions govern clinical position, switching, access, launch execution, and portfolio durability.
Decision Environments
Engagements begin at different points, but the governing constraints often cross the boundaries of the initial request.
Regulatory & Access Pathways
Filing logic, label conditions, evidence requirements, reimbursement, pathway position, and country-level adoption constraints.
Launch & Commercial Architecture
Market preparation, field-force and medical roles, account coverage, channel structure, patient support, and launch sequencing.
Manufacturing & Delivery
Capacity, supply, configuration, administration, device or site readiness, and the relationship between operational uncertainty and asset value.
Patient & Treatment Systems
Patient identification, referral patterns, specialist pathways, administration burden, monitoring, persistence, and continuity of treatment.
Longitudinal Competitive Monitoring
Clinical, regulatory, access, organization, and commercial signals reconstructed across multi-phase and multi-year programs.
Evidence Architecture
The evidence base is developed through source calls and interviews positioned close to the decisions, constraints, and operating conditions being reconstructed.
Clinical & Investigator Side
Key opinion leaders, principal investigators, study-site personnel, treating specialists, centers of excellence, diagnostic pathways, and investigator-side clinical teams.
Company-Side Sources
Clinical development, regulatory, medical affairs, CMC and manufacturing, market access, patient services, field leadership, commercial, and portfolio functions.
Access & Operating Systems
Payer and reimbursement environments, procurement, distribution, treatment centers, testing providers, administration systems, patient-support infrastructure, and local access pathways.
Triangulation
Interview evidence is tested against clinical, regulatory, manufacturing, access, and organizational signals and against the criteria used by reviewers, payers, clinicians, partners, and other decision-makers.
Selected Project Record
Selected engagements across dermatology.
The projects below are selected from a substantially larger body of work. They were chosen to illustrate different decision environments, lifecycle stages, modalities, geographies, and forms of engagement. The selection is illustrative rather than exhaustive. Multi-phase and longitudinal assignments may be presented as a single project title, and company, asset, or market details may be generalized where appropriate.
Clinical Development & Data
- Development and Commercialization Assessment of Therapies for Atopic Dermatitis and Prurigo Nodularis
- Clinical-Development Assessment of Biologics in Chronic Spontaneous Urticaria
- Competitive Clinical Positioning of IL-23, IL-17 and TYK2 Therapies in Psoriasis
- Trial and Label-Scenario Assessment for Topical Therapies in Atopic Dermatitis
Regulatory, Access & Adoption
- Pricing and Generic-Entry Architecture for Topical Dermatology Therapies in Europe and the United States
- Market-Access and Switching Assessment for Psoriasis Biologics
- Reimbursement and Adoption Architecture for Atopic-Dermatitis Therapies in Europe
- Access Assessment for Novel Dermatology Therapies in Selected International Markets
Launch & Commercial Architecture
- Longitudinal Competitive and Launch Monitoring of Biologic Therapies in Psoriasis Across Europe
- Field-Force and Medical-Organization Benchmarking in Psoriasis Across Selected European Markets
- Launch Architecture for Biologic Therapies in Atopic Dermatitis
- Commercial Assessment of Topical Combination Therapies in Europe and the United States
Manufacturing, Delivery & Systems
- Device and Packaging Assessment for Self-Injected Dermatology Biologics
- Manufacturing and Supply Assessment for Topical Dermatology Generics
- Patient-Support and Administration Architecture for Biologics in Dermatology
Longitudinal Monitoring & Portfolio
- Longitudinal Monitoring Across Psoriasis, Atopic Dermatitis and Prurigo Nodularis
- Competitive Monitoring of Topical and Systemic Dermatology Portfolios
- Multi-Market Monitoring of Dermatology Pricing, Access and Field Organization
Dermatology Engagements
ICG can enter at the level of a single critical question, a multi-market evidence program, or a longitudinal clinical, regulatory, manufacturing, access, commercial, or operating-system decision environment.